Vetoquinol SA (EPA:VETO)

France flag France · Delayed Price · Currency is EUR
83.90
-0.80 (-0.94%)
Mar 2, 2026, 5:35 PM CET
15.72%
Market Cap 989.66M
Revenue (ttm) 532.39M
Net Income (ttm) 59.96M
Shares Out 11.80M
EPS (ttm) 5.10
PE Ratio 16.46
Forward PE 15.53
Dividend 0.89 (1.05%)
Ex-Dividend Date Jun 4, 2025
Volume 3,053
Average Volume 2,425
Open 83.10
Previous Close 84.70
Day's Range 75.00 - 83.90
52-Week Range 68.70 - 91.50
Beta 1.02
RSI 42.29
Earnings Date Mar 27, 2026

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA. [Read more]

Sector Healthcare
Founded 1933
Employees 2,497
Stock Exchange Euronext Paris
Ticker Symbol VETO
Full Company Profile

Financial Performance

In 2024, Vetoquinol's revenue was 539.20 million, an increase of 1.88% compared to the previous year's 529.27 million. Earnings were 58.69 million, an increase of 5.62%.

Financial Statements

News